Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: Zosuquidar trihydrochloride
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang
Email: enquiry@dycnchem.com

167465-36-3

167465-36-3 structure

167465-36-3 structure

Name: Zosuquidar trihydrochloride
Chemical Name: Zosuquidar Trihydrochloride
CAS Number: 167465-36-3
Molecular Formula: C₃₂H₃₄Cl₃F₂N₃O₂
Molecular Weight: 636.987
Catalog: Biochemical Inhibitor Transmembrane Transporters P-gp regulator
Create Date: 2018-02-14 08:00:00
Modify Date: 2026-07-01 18:04:44
Zosuquidar trihydrochloride is an inhibitor of P-glycoprotein with a Ki value of 59 nM.

Name	Zosuquidar Trihydrochloride
Synonyms	ZOSUQUIDTRIHYSROCHLORIDE ZOSUQUIDTRIHYSROCHLORIDE //BP LY335979, RS 33 RS 33(D06387) 3HCl Zosuquid(LY335979 LY335979（167-3） Zosuquidtrihydrochloride LY335979 Zosuquidar (trihydrochloride) RS-33295-198; ZOSUQUID; LY-335979 RS-33295-198, ZOSUQUID Zosuquid(LY335979) triHydrochloride ZosuquidTrihydrochloride Zosuquid(RS 33 Zosuquidtrihydrochloride (LY-335979 trihydrochloride) 1-Piperazineethanol,4-[(1aa,6a,10ba)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohten-6-yl]-a-[(5-quinolinyloxy)methyl]-,hydrochloride (1:3) D06387 Zosuquidr.3HCl (R)-4-[(1aR,6R,10bS)-1,2-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cycloheptan-6-yl]-α-[(5-quinoloyloxy)methyl]-1-piperazineethanol trihydrochloride Zosuquid3HCl RS 33 (αR)-4-[(1aα,6α,10bα)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohten-6-yl]-α-[(5-quinolinyloxy)Methyl]-1-piperazineethanol Hydrochloride LY335979 (Zosuquidtrihydrochloride) 1-Piperazineethanol, 4-[(1aα,6α,10bα)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohten-6-yl]-α-[(5-quinolinyloxy)methyl]-,trihydrochloride N'-(3-pyridylmethyl)butane-1,4-diamine Zosuquidtrihydrochloride 3HCL Trihydrochloride Zosuquidar 3HCl Levodropropizine Impurity 12 Zosuquid(LY335979) 3HCl [6(R)-(1aα,6α,10bα)]-4-(1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohten-6-yl)-α-[(5-quinolinyloxy)Methyl]-piperazineethanol trihydrochloride, (2R)-anti-5-{3-[4-(10,11-difluoroMethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy (2R)-1-{4-[(1aR,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl]-1-piperazinyl}-3-(5-quinolinyloxy)-2-propanol trihydrochloride LY335979 (Zosuquid3HCl) Zosuquidtrihydrochloride, 10 mM in DMSO LY335979 (αR)-4-[(1aα,6α,10bα)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohten-6-yl]-α-[(5-quinolinyloxy)methyl]-1-piperazineethanol trihydrochloride 1-Piperazineethanol, 4-[(1aR,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-α-[(5-quinolinyloxy)methyl]-, (αR)-, hydrochloride (1:3) LY335979(Zosuquid/Zosuquidtrihydrochloride, RS-33295-198 1-(3-aminocyclopentyl)-N,N-dimethyl-pyrrolidin-3-amine CEM/VLB100,Pgp,2780AD,Multidrug resistance protein 1,CD243,anti-tumor activity,P388/ADR,P-glycoprotein,UCLA-P3.003VLB,2780,ABCB1,MCF7,acute myelogenous leukemia,MDR1,HL60,P-gp,UCLA-P3,P388,MCF7/ADR,CCRF-CEM,K562,Inhibitor,Zosuquidtrihydrochloride,Cluster of differentiation 243,AML,inhibit LY 335979; LY-335979; LY335979; D06387; RS33295198 (2R)-1-{4-[(1,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol trihydrochloride RS 33trihydrochloride (2R)-1-{4-[(1,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol trihydrochloride Zosuquidtrihydrochloride LY335979 Zosuquidr.3HCl(LY335979) LY-335979 trihydrochloride LY335979) 3HCl ZosuquidHCl 4-piperazin-1-ylpyrrolidin-2-one ZosuquidTriHCl Zosuquidtrihydrochloride, >= (R)-1-(4-((1,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]annulen-6-yl)piperazin-1-yl)-3-(quinolin-5-yloxy)propan-2-ol trihydrochloride methyl (4R)-4-[(3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-[4-(3-pyridylmethylamino)butylamino]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate

Description	Zosuquidar trihydrochloride is an inhibitor of P-glycoprotein with a Ki value of 59 nM.
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> P-glycoprotein Research Areas >> Cancer
Target	Ki: 59nM (P-glycoprotein)[1].
In Vitro	Zosuquidar completely or partially restores drug sensitivity in all P-gp-expressing leukemia cell lines and enhances the cytotoxicity of anthracyclines (daunorubicin, idarubicin, mitoxantrone) and gemtuzumab ozogamicin (Mylotarg) in primary AmL blasts with active P-gp. In addition, P-gp inhibition by zosuquidar is found to be more potent than cyclosporine A in cells with highly active P-gp[2].
In Vivo	Zosuquidar trihydrochloride is only moderately active as an inhibitor of P-gp at the blood-brain. An oral dose of 25 mg/kg of zosuquidar trihydrochloride increases the brain concentrations by about 2.5-fold at 1 h and 5-fold at 24 h after paclitaxel administrationbarrier[3]. Zosuquidar enhances the brain uptake of nelfinavir in a dose-dependent manner. Brain tissue/plasma nelfinavir concentration ratios increase from 0.06±0.03 in the absence of zosuquidar administration and 0.09±0.02 between 2 and 6 h after a 2 mg/kg intravenous dose of zosuquidar to 0.85±0.19 after 6h and 1.58±0.67 after 20 mg/kg zosuquidar[4].
Cell Assay	Cells are cultured in 96-well plates. Each drug of interest is added at escalating concentrations in the presence or absence of either zosuquidar or CsA. After 48 hour incubation (except Mylotarg, 4 days incubation), 20 μL of MTT is added to each well for a further 4 hour incubation. The purple precipitate is dissolved in 200 μL DMSO, and the optic density (OD) is determined by the multi-well plate reader[2].
Animal Admin	Rats: Female Sprague-Dawley rats are used in the study. Zosuquidar solutions are prepared in 5% mannitol and adjusted to pH ～2.0 with concentrated HCl. Nelfinavir is infused (10 mg/kg/h) for up to 10 h with or without concurrent administration of an intravenous bolus dose of 2, 6, or 20 mg/kg zosuquidar given at 4 h. Brain tissue and plasma are analyzed for both drug concentrations[4]. Mice: A stock solution of 5 mg/mL of zosuquidar trihydrochloride is prepared in vehicle solution and diluted in sterile saline. The vehicle solution consisted of 20 g/l mannitol and 1.5 g/l of glycine in water for injection and adjusted to a pH of 2.7 with hydrochloric acid. P-gp knockout mice and wild type mice are used as a model for complete inhibition of P-gp. Zosuquidar trihydrochloride is administered orally at 25 and 80 mg/kg 1 h before i.v. paclitaxel and i.v. at 20 mg/kg 10 min and 1 h before paclitaxel. The concentrations of paclitaxel in plasma and tissues and of zosuquidar trihydrochloride in plasma are quantified by high-performance liquid chromatography[3].
References	[1]. Cripe LD, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood.?201 [2]. Tang R, et al. Zosuquidar?restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AmL). BMC Cancer.?2008 Feb 13;8:51.? [3]. Kemper EM, et al. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol. 2004 Feb;53(2):173-8. [4]. Anderson BD, et al. Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats. Drug Metab Dispos. 2006 Apr;34(4):653-9. [5]. Hou J, et al. Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012 Jul;66:232-9.

Boiling Point	690.5ºC at 760mmHg
Melting Point	172-176°C
Molecular Formula	C₃₂H₃₄Cl₃F₂N₃O₂
Molecular Weight	636.987
Flash Point	371.4ºC
Exact Mass	635.168457
PSA	48.83000
LogP	7.49320
Storage condition	Hygroscopic, -20?C Freezer, Under Inert Atmosphere

Hazard Codes	Xi

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.